Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.
A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback